Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Genesis Research Derives Surplus

Genesis Research Derives Surplus From Fourfold Revenue Increase

Auckland, New Zealand, 31 January 2001 – Genesis Research [NZSE & ASX: GEN] today announced a Net Surplus for the year ended 31st December 2000 of $723,000. This compares with a deficit of $7.15 million for the previous year and the $9.97 million loss forecast in the company’s recent investment statement and prospectus. The improved results were achieved through Genesis sublicensing its PVAC™ vaccine for the treatment of psoriasis to partners in Japan and North America, as a result of which total operating income effectively quadrupled to $28.66 million (up 298% from $7.19 million).

The company finished the year with cash reserves of $61.93 million as a result of the receipt of these upfront licensing payments and the capital raising undertaken during the year.

In accordance with the policy of the Board, as noted in the August 2000 investment statement and prospectus, no dividend will be paid.

The increased revenues, together with the successful capital raising programme enabled Genesis to increase expenditure on research and development to $18.9 million, up 58% from $11.9 million in 1999. Funds were applied to research into new therapeutics and other potential products as well as the Phase II Clinical trials currently being conducted in USA, Brazil and Philippines. Genesis has not received the results of these trials yet but expects to announce the results of the USA trial early in February. At 31st December Genesis’ 24 hour 7 day sequencing facility had developed over 1 million EST sequences in its database. This now includes the largest forestry tree EST collection in the world, as well as specialised human, bovine, ovine, cervine, fruit tree, forage grass and microbe databases.

“As this result shows, the prime beneficiary of Genesis’ revenue growth and capital raising is our enhanced research programme,” said Founder and CEO Dr James Watson. “To operate from this solid base gives us an immense advantage in what is a highly competitive environment.”

Staff numbers rose during the year from 83 to 124 through an active national and international recruitment programme.

About Genesis
Genesis is a New Zealand-based biotechnology company whose core business is genomics – the translation and use of the chemical information carried within genes of living organisms. Genesis specialises in discovery, building EST databases from a diverse range of carefully selected gene pools, targeting genes, promoters or proteins that have commercial value through their potential ability to alter a living process or to create a new industrial process. Genesis is not a manufacturer or distributor of products: it mines these databases, and uses collaboration with industry partners, to develop innovative biotechnology products of commercial value from its discovery activities. Genesis has vaccine therapeutics in clinical trials which are novel because they can be used to treat immune disorders not generally caused by infection. Genesis also uses technologies applied in the health field to develop novel products in the areas of agriculture, horticulture and forestry in which our New Zealand primary producer partners lead the world.

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>

Earlier:

Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>

ALSO:

Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>

ALSO:

Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

ALSO:

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news